Emtricitabine, rilpivirine, and tenofovir and Levonorgestrel and ethinyl estradiol interaction
Emtricitabine, rilpivirine, and tenofovir and Levonorgestrel and ethinyl estradiol: the Emtricitabine, rilpivirine, and tenofovir prescribing label reports no clinically significant interaction between these two.
No clinically significant interaction reported. The label studied or considered this pair and found nothing meaningful.
What the FDA labels say
From the Emtricitabine, rilpivirine, and tenofovir (COMPLERA) label · effective 2025-07-16
No clinically significant drug interactions have been observed between RPV and the following medications: acetaminophen, atorvastatin, chlorzoxazone, ethinyl estradiol, ledipasvir/sofosbuvir, norethindrone, sildenafil, simeprevir, sofosbuvir, sofosbuvir/velpatasvir, sofosbuvir/velpatasvir/voxilaprevir, or TDF.
No clinically significant drug interactions have been observed between TDF and the following medications: entecavir, methadone, oral contraceptives, ribavirin, sofosbuvir, or tacrolimus in studies conducted in healthy subjects.
Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.
Open in the checkerNot medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.